Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep;37(3):364-371.
doi: 10.5534/wjmh.180084. Epub 2019 Jan 4.

The Relationships between Thyroid Hormone Levels and Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia

Jun Ho Lee  1 , Yeon Won Park  1 , Sung Won Lee  2
Affiliations

The Relationships between Thyroid Hormone Levels and Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia

Jun Ho Lee et al. World J Mens Health. 2019 Sep.

Abstract

Purpose: We examined the association between thyroid hormone and lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH).

Materials and methods: A total of 5,708 middle aged men were included. LUTS/BPH were assessed using the international prostate symptom score (IPSS), total prostate volume (TPV), maximal flow rate (Qmax), and a full metabolic workup. Thyroid stimulating hormone (TSH) and free thyroxine (FT4) levels were measured using chemiluminescence immunoassay. We divided participants into quartiles based on their TSH and FT4 levels: first to fourth quartile (Q1-Q4).

Results: There was a significant increase in the percentage of men with IPSS>7, Qmax<10 mL/s, and TPV≥30 mL with increase of FT4 quartile. The adjusted odds ratio (OR) for TPV≥30 mL and IPSS>7 were significantly different between FT4 quartile groups (ORs; [5-95 percentile interval], p; TPV≥30 mL, Q1: 0.000 [references]; Q2: 1.140 [0.911-1.361], p=0.291; Q3: 1.260 [1.030-1.541], p=0.025; Q4: 1.367 [1.122-1.665], p=0.002; IPSS>7: Q1: 0.000 [references]; Q2: 0.969 [0.836-1.123], p=0.677; Q3: 1.123 [0.965-1.308], p=0.133; Q4: 1.221 [1.049-1.420], p=0.010). In men with above median levels of testosterone, the FT4 correlated positively with TPV, even after adjusting for confounders. However, the FT4 was not correlated with TPV in men with below median levels of testosterone. TSH was not related to LUTS/BPH measurements.

Conclusions: TPV, IPSS, and Qmax were significantly related to FT4. TPV and IPSS were significantly and independently related to FT4. Additionally, the relationship between FT4 and TPV was distinct when testosterone levels are high.

Keywords: Prostate; Prostatic hyperplasia; Testosterone; Thyroid; Urinary tract diseases.

PubMed Disclaimer

Conflict of interest statement

The authors have no potential conflicts of interest to disclose.

Figures

Fig. 1
Fig. 1. Relationships between FT4 and LUTS/BPH measurements. Values are presented as number (%). Cochran-Armitage trend test were used for statistical analysis. FT4: free thyroxine, LUTS: lower urinary tract symptoms, BPH: benign prostatic hyperplasia, TPV: total prostate volume, IPSS: international prostate symptom score, Qmax: maximal flow rate, PVR: postvoid residual urine volume, PSA: prostate specific antigen, Q1: first quartile, Q2: second quartile, Q3: third quartile, Q4: fourth quartile. *p-value statistically significant <0.05.
Fig. 2
Fig. 2. Relationships between TSH and LUTS/BPH measurements. Values are presented as number (%). Cochran-Armitage trend test were used for statistical analysis. TSH: thyroid stimulating hormone, LUTS: lower urinary tract symptoms, BPH: benign prostatic hyperplasia, TPV: total prostate volume, IPSS: international prostate symptom score, Qmax: maximal flow rate, PVR: postvoid residual urine volume, PSA: prostate specific antigen, Q1: first quartile, Q2: second quartile, Q3: third quartile, Q4: fourth quartile.
See this image and copyright information in PMC

References

    1. Ziada A, Rosenblum M, Crawford ED. Benign prostatic hyperplasia: an overview. Urology. 1999;53(3 Suppl 3a):1–6. - PubMed
    1. La Vignera S, Condorelli RA, Russo GI, Morgia G, Calogero AE. Endocrine control of benign prostatic hyperplasia. Andrology. 2016;4:404–411. - PubMed
    1. Hercbergs A. The thyroid gland as an intrinsic biologic response-modifier in advanced neoplasia: a novel paradigm. In Vivo. 1996;10:245–247. - PubMed
    1. Moeller LC, Führer D. Thyroid hormone, thyroid hormone receptors, and cancer: a clinical perspective. Endocr Relat Cancer. 2013;20:R19–R29. - PubMed
    1. Anil C, Guney T, Gursoy A. The prevalence of benign breast diseases in patients with nodular goiter and Hashimoto's thyroiditis. J Endocrinol Invest. 2015;38:971–975. - PubMed